A Study of Oral TP-3654 in Patients With Myelofibrosis
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 1, multicenter, dose-escalation, open-label trial to assess safety,
tolerability, pharmacokinetics and pharmacodynamics of TP-3654 in patients with intermediate
or high-risk primary or secondary MF.
Phase:
Phase 1
Details
Lead Sponsor:
Boston Biomedical, Inc Sumitomo Dainippon Pharma Oncology, Inc